Cognition Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Cognition Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH135673D
  • |
  • Pages: 36
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Cognition Therapeutics Inc (CogRx) is a drug discovery and development company that discovers and develops small molecule therapeutics to improve the lives of individuals with Alzheimer's disease and other neurocognitive disorders. The company uses its proprietary biology and chemistry platforms for the development of novel drug targets and disease modifying therapies for the treatment of central nervous system disorders. It conducts clinical trials on its drug candidate CT1812 for the treatment of Alzheimer's disease. The company uses screening strategies to identify small molecules capable of blocking the central toxicity of soluble oligomeric proteins. CogRx is headquartered in Pittsburgh, Pennsylvania, the US.

Cognition Therapeutics Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Cognition Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Cognition Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Cognition Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Cognition Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Cognition Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Cognition Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

Cognition Therapeutics Raises USD2.4 Million in Venture Financing 10

Cognition Therapeutics Raises USD3 Million in Venture Financing 11

Cognition Therapeutics Raises USD3.5 Million Financing 12

Cognition Therapeutics Raises USD12 Million in Series B Venture Financing 13

Cognition Therapeutics Secures USD15.83 Million in Series B Funding 15

Cognition Therapeutics Raises USD 0.14 Million In Venture Financing 16

Cognition Therapeutics Raises USD 2 Million In Venture Financing 17

Cognition Therapeutics Inc-Key Competitors 18

Cognition Therapeutics Inc-Key Employees 19

Cognition Therapeutics Inc-Locations And Subsidiaries 20

Head Office 20

Recent Developments 21

Corporate Communications 21

Aug 02, 2017: Cognition Therapeutics Elects Lazard Vice Chairman Stephen Sands to Board of Directors 21

Product News 22

11/08/2017: Cognition Therapeutics CEO Kenneth I. Moch to Present at the Stifel 2017 Healthcare Conference 22

11/04/2017: Cognition Therapeutics' Alzheimer's Disease Candidate CT1812 Meets Phase 1b/2a Study Objectives: Well Tolerated with Positive Influence on Biomarkers of Synapse Recovery 23

10/30/2017: Cognition Therapeutics to Present Results of CT1812 Phase 1b/2a Clinical Study as Late Breakers at CTAD Meeting 24

09/07/2017: Cognition Therapeutics CEO Kenneth I. Moch Hosting One-on-Ones at Mizuho Securities CNS Deep Management Day 25

08/23/2017: Function of Cognition Therapeutics' Neurological Drug Screening Platform Presented at American Chemical Society National Meeting 26

07/31/2017: Cognition Therapeutics CEO Kenneth I. Moch to Present at Canaccord Genuity Annual Growth Conference 27

04/03/2017: Cognition Therapeutics CEO Kenneth I. Moch Presenting at BioCentury Future Leaders Conference 28

03/06/2018: Cognition Therapeutics Co-Founder and CSO Susan Catalano to Present at the Annual ASENT Meeting 29

02/12/2018: Cognition Therapeutics to Participate in Leerink Partners 7th Annual Global Healthcare Conference 30

01/04/2018: Cognition Therapeutics Co-Founder and CSO Susan Catalano to Present at Sachs Neuroscience Innovation Forum 31

Product Approvals 32

Oct 16, 2017: Cognition Therapeutics Receives Fast Track Designation from U.S. FDA for First-in-Class Alzheimer's Candidate, CT1812 32

Clinical Trials 33

Mar 14, 2018: Cognition Therapeutics Presenting Evidence for Elayta Synaptic Protection in Alzheimer's Patients at Combined AAT-AD/PD Focus Meeting 33

Jul 19, 2017: Cognition Therapeutics Reports Drug-Drug Interaction Results for CT1812, a Disease-Modifying Alzheimer's Disease Candidate 34

Appendix 35

Methodology 35

About GlobalData 35

Contact Us 35

Disclaimer 35

List of Figures

Cognition Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Cognition Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Cognition Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Cognition Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Cognition Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cognition Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Cognition Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cognition Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

Cognition Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2

Cognition Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cognition Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Cognition Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cognition Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Cognition Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Cognition Therapeutics Raises USD2.4 Million in Venture Financing 11

Cognition Therapeutics Raises USD3 Million in Venture Financing 12

Cognition Therapeutics Raises USD3.5 Million Financing 13

Cognition Therapeutics Raises USD12 Million in Series B Venture Financing 14

Cognition Therapeutics Secures USD15.83 Million in Series B Funding 16

Cognition Therapeutics Raises USD 0.14 Million In Venture Financing 17

Cognition Therapeutics Raises USD 2 Million In Venture Financing 18

Cognition Therapeutics Inc, Key Competitors 19

Cognition Therapeutics Inc, Key Employees 20

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

select a license
Single User License
USD 250 INR 17500
Site License
USD 500 INR 35000
Corporate User License
USD 750 INR 52500

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com